NCT02549196View on ClinicalTrials.gov

A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 7, 2015

Primary Completion Date

September 28, 2017

Study Completion Date

September 28, 2017

Conditions
Dementia of Alzheimer's Type
Interventions
DRUG

Donepezil

Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.

DRUG

Solifenacin

Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.

Trial Locations (4)

27103

PMG Research, Winston-Salem

33064

Quantum Laboratories, Deerfield Beach

33137

Miami Jewish Health Systems, Miami

33407

Premiere Research Institute, West Palm Beach

All Listed Sponsors
lead

Chase Pharmaceuticals Corporation, an affiliate of Allergan plc

INDUSTRY

NCT02549196 - A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type | Biotech Hunter | Biotech Hunter